Z-1125-2019 Class II Terminated

Recalled by Roche Diagnostics Corporation — Indianapolis, IN

FDA device recall Z-1125-2019 was initiated by Roche Diagnostics Corporation on Dec 14, 2018 and is designated Class II. Reason for recall: COBAS INTEGRA¿ 400 plus and cobas c 111 analyzers Additional Extra Wash Cycle Configurations and/or Batch Mode Needed for Specific Tests Due to Carry-over The recall status is terminated (terminated Sep 4, 2020). Affected quantity: 137 units.

Recall details

Product Type
Devices
Report Date
Apr 17, 2019
Initiation Date
Dec 14, 2018
Termination Date
Sep 4, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
137 units

Product description

cobas c 111 with ISE analyzers analyzer used in the following assays: a)Creatinine plus ver.2 Catalog Number: 05401470190; b)Triglycerides Catalog Number: 04657594190 - Product Usage: Tina-quant Apolipoprotein A-1 ver.2 A lipoprotein test system is a device intended to measure lipoprotein in serum and plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders and atherosclerosis Tina-quant Albumin Gen.2 Immunoturbidimetric assay for the quantitative, in vitro determination of albumin in human urine, serum, plasma, and CSF on Roche/Hitachi cobas c systems

Reason for recall

COBAS INTEGRA¿ 400 plus and cobas c 111 analyzers Additional Extra Wash Cycle Configurations and/or Batch Mode Needed for Specific Tests Due to Carry-over

Distribution pattern

US Nationwide distribution.

Code information

All

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-1125-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-1125-2019. Report a data issue: hello@regdatalab.com.